Company Encyclopedia
View More
name
huahaipharm
600521.SH
Zhejiang Huahai Pharmaceutical Co., Ltd. engaged in the research, development, production and sales of generic drugs, biological drugs, and APIs in multiple dosage forms in China and internationally. The company offers central neurological, cardiovascular, anti-viral, and other products, as well as APIs and intermediates. It also provides packaging components, such as polyethylene bottles and polypropylene caps for pharmaceuticals.
3.099 T
600521.SHMarket value -Rank by Market Cap -/-

Financial Score

23/12/2025 Update
C
PharmaceuticalsIndustry
Industry Ranking85/223
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreC
    • ROE5.11%C
    • Profit Margin5.37%C
    • Gross Margin60.72%A
  • Growth ScoreD
    • Revenue YoY-6.85%D
    • Net Profit YoY-58.95%D
    • Total Assets YoY8.17%B
    • Net Assets YoY7.20%B
  • Cash ScoreC
    • Cash Flow Margin1860.55%A
    • OCF YoY-6.85%D
  • Operating ScoreC
    • Turnover0.43C
  • Debt ScoreC
    • Gearing Ratio54.62%C

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Huahaipharm's subsidiary, Ruixiqi's Bevacizumab Injection marketing authorization application has been accepted

    Huahaipharm's subsidiary, Huaotai, recently received the acceptance notice for the marketing authorization application of Reciqi Bai Injection from the National Medical Products Administration. This drug is used for the treatment of adult generalized pustular psoriasis (GPP) and is the first domestically developed anti-IL-36R antibody, demonstrating good safety and efficacy

    Zhitong·
    SH
    600521
    -1.68%
    Zhitong·
    SH
    600521
    -1.68%

    Huahaipharm: Carboxymethyl Sodium Injection has obtained a drug registration certificate

    According to the Zhitong Finance APP, Huahai Pharmaceutical announced that the company recently received the "Drug Registration Certificate" for Carbetocin Injection issued by the National Medical Products Administration. Carbetocin Injection is used for bleeding diseases in the urinary system, upper digestive tract, respiratory tract, and obstetrics and gynecology, showing significant efficacy in the urinary system, and can also be used for the prevention and treatment of surgical bleeding, among other uses

    Zhitong·
    SH
    600521
    -1.68%
    Zhitong·
    SH
    600521
    -1.68%

    Huahaipharm: Huaotai has received FDA approval to conduct Phase I clinical trials of injectable HB0043 in the United States

    Huahaipharm's subsidiary Huaotai has received FDA approval to conduct Phase I clinical trials of injectable HB0043 in the United States. HB0043 is a bispecific antibody targeting IL-17A and IL-36R, with high binding and blocking activity, aimed at treating various autoimmune diseases. Compared to monoclonal antibodies, HB0043 demonstrates stronger performance in suppressing inflammation and fibrotic responses, potentially providing new treatment ideas for immune-mediated inflammatory skin diseases and fibrotic diseases

    Zhitong·
    SH
    600521
    -1.68%
    Zhitong·
    SH
    600521
    -1.68%

    Huahaipharm: Two products have obtained drug registration certificates

    Huahaipharm recently obtained two drug registration certificates approved by the National Medical Products Administration, including Candesartan Cilexetil and Hydrochlorothiazide Tablets (II) and Injection of Rosuvastatin Acetate. The approval for the production of these two products can be regarded as passing the consistency evaluation, further enriching the company's product line, enhancing market competitiveness, and having a positive impact on the company's operational development

    Zhitong·
    SH
    600521
    -1.68%
    Zhitong·
    SH
    600521
    -1.68%

    Innovative drug concept stocks show partial strength, Thalys hits the limit up

    Innovative drug concept stocks are showing strength in parts, with Thalys hitting the limit up, Cosunter rising over 7%, and EASTON BIOPHARMACEUTICALS, huahaipharm, JOINN, and Enhua Pharmaceutical following suit

    Zhitong·
    SH
    603127
    +1.27%
    HK
    06127
    +4.23%
    SZ
    300436
    -0.44%
    Zhitong·
    SH
    603127
    +1.27%
    HK
    06127
    +4.23%
    SZ
    300436
    -0.44%
    © 2025 Longbridge｜Disclaimer